Triple-negative breast cancers (TNBCs, lacking the expression of estrogen and progesterone receptors, as well as human epidermal growth factor receptor 2, HER229) are aggressive and associated with the poorest outcomes30–33. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.